Skip to main content
Funded Studies

Assessing the Ability of Neuronal Modulators to Treat or Modify the Motor Symptoms of Parkinson’s Disease

Study Rationale: The dopamine-producing cells that are lost in Parkinson’s disease (PD) express a unique type of cell-surface protein called the M5 muscarinic acetylcholine receptor. The presence of this unique receptor presents a unique opportunity to correct the changes in activity induced in these neurons by the accumulation of pathological forms of alpha-synuclein.

Hypothesis:Our broad hypothesis is that activation of the M5 receptor could be used as a novel therapeutic strategy for the treating the symptoms, and perhaps modifying the cause of the underlying disease, in people with PD.

Study Design: To test our hypothesis, we will use a multidisciplinary approach to understand how the M5 receptor interacts with the “parkinsonian state.” To do this we, will examine how M5 receptors alter the firing rates of dopamine-producing neurons and affect the changes in motor behavior in preclinical models of PD.

Impact on Diagnosis/Treatment of Parkinson’s disease: The successful completion of these studies will provide the preclinical rationale for the development of M5 modulators for the symptomatic and possibly disease-modifying treatment of PD.

Next Steps for Development: The next steps would require medicinal chemistry efforts to develop M5 modulators that can reach the relevant brain regions and have suitable pharmacokinetic properties for clinical use.


  • Mark Stephen Moehle, PhD

    Gainesville, FL United States

Discover More Grants

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.